The medication program that monitors the risk of severe neutropenia is:
- Clozapine REMS
Clozapine is an antipsychotic medication that can lead to a serious condition called neutropenia, which is a decrease in a type of white blood cell that helps fight off infections. To mitigate this risk, the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program was established to monitor patients for the development of neutropenia and ensure they receive appropriate monitoring and care to prevent severe complications. Through this program, healthcare providers and patients work together to monitor blood counts regularly and manage any potential side effects promptly. This program aims to enhance patient safety and minimize the risks associated with clozapine treatment.
